// App-Quantinova.ai

2892 : The Valproic Acid-Fludarabine Combination Induces a Synergistic Response in Chronic Lymphocytic Leukemia Via a Mechanism Involving the Lysosomal Protease Cathepsin B.

Researchers

Presenter

  • David Szwajcer

Principal Investigators

  • Ganchimeg Ishdorj

  • Pat Benjaminson

  • James B Johnston

  • Spencer B Gibson

Medical Centers

  • Dept. of Hematology, CancerCare Manitoba and the University of Manitoba, Winnipeg, MB, Canada

  • Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada

  • Department of Biochemistry & Manitoba Institute of Cell Biology, CancerCare Manitoba, Winnipeg, MB, Canada

  • Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada

  • Department of Internal Medicine, Section of Hematology/Oncology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • Myeloid Cell Leukemia 1

  • X-linked inhibitor of apoptosis

Drug/Treatment

  • Vorinostat

  • trichostatin A

  • Valproic Acid

  • Valproate

  • chloroquine

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved